The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is caused by an LMNA mutation that results in the production of the abnormal progerin protein. Children with HGPS display phenotypes of premature aging and have an average lifespan of 13 years. We found earlier that the targeting of the transmembrane protein PLA2R1 overcomes senescence and improves phenotypes in a mouse model of progeria. PLA2R1 is regulating the JAK/STAT signaling, but we do not yet know whether targeting this pathway directly would influence cellular and in vivo progeria phenotypes. Here, we show that JAK1/2 inhibition with ruxolitinib rescues progerin‐induced cell cycle arrest, cellular senescence, and misshapen nuclei in human normal fibroblasts expressing progerin. Moreover, ruxolitinib administration reduces several premature aging phenotypes: bone fractures, bone mineral content, grip strength, and a trend to increase survival in a mouse model of progeria. Thus, we propose that ruxolitinib, an FDA‐approved drug, should be further evaluated as a drug candidate in HGPS therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801
Self-citationSenescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284 · cited 1×
“The functional involvement of cellular senescence in promoting aging and age-related pathologies has been confirmed during the last few years (Childs et al., 2017).”
BackgroundTargeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182
Goldman, R. D., Shumaker, D. K., Erdos, M. R., Eriksson, M., Goldman, A. E., Gordon, L. B., Gruenbaum, Y., Khuon, S., Mendez, M., Varga, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402943101 · Cited by 1,103 · cited 1×
“HGPS is caused by a mutation in the LMNA gene, leading to the production of progerin, a truncated prelamin A form, which induces misshapen nuclei, cellular senescence, and aging (Goldman et al., 2004).”
BackgroundXu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915 · cited 5×
“…the cell cycle arrest associated with PLA2R1-induced senescence, thus affecting senescence beyond the sole inhibition of the SASP as described by others (Farr et al., 2017; Xu et al., 2015, 2016) or/and because the SASP can be also a critical mediator of the full senescence (Acosta et al., 2008).”
BackgroundInfluentialOsorio, F. G., Bárcena, C., Soria-Valles, C., Ramsay, A. J., de Carlos, F., Cobo, J., Fueyo, A., Freije, J. M. P., & López-Otín, C. (2012) · Genes & Development · doi:10.1101/gad.197954.112 · Cited by 276 · cited 9×
“Statistical analyses were performed using the two-sided Student's t test for (a) and (b) and the log-rank test Whole bodyHind leg (a) (b) (c) (d) new strategy (Gordon et al., 2016, 2012) to improve the health of children with HGPS.”
BackgroundInfluentialPerspective: Targeting the JAK/STAT pathway to fight age-related dysfunction
Xu, M., Tchkonia, T., & Kirkland, J. L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.015 · Cited by 99 · cited 4×
“Overall, these results confirm that JAK1/2 inhibition by ruxolitinib impacts not only the secretome of senescent cells, as already suggested by others (Farr et al., 2017; Xu et al., 2015, 2016), but also the cell cycle arrest, which can itself be induced by the SASP (Acosta et al., 2008).”
BackgroundInfluential
Cited by
Cellular senescence: a key therapeutic target in aging and diseases
Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., & Zhu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158450 · Cited by 631
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023) · The FEBS Journal · doi:10.1111/febs.16350 · Cited by 621
Interleukin‐6 neutralization ameliorates symptoms in prematurely aged mice
Squarzoni, S., Schena, E., Sabatelli, P., Mattioli, E., Capanni, C., Cenni, V., D'Apice, M. R., Andrenacci, D., Sarli, G., Pellegrino, V., et al. (2021) · Aging Cell · doi:10.1111/acel.13285 · Cited by 72
Advancements in therapeutic drugs targeting of senescence
Zhu, M., Meng, P., Ling, X., & Zhou, L. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320964125 · Cited by 68
Metadata
- Authors
- Griveau, A., Wiel, C., Ziegler, D. V., Bergo, M. O., & Bernard, D.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2020-03-20
- Volume
- 19
- Issue
- 4
- Pages
- e13122-e13122
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W3012106404
- Cited by
- 76
- References
- 7
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.